PE20211734A1 - Analogos de peptidos de conotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias - Google Patents

Analogos de peptidos de conotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias

Info

Publication number
PE20211734A1
PE20211734A1 PE2021001115A PE2021001115A PE20211734A1 PE 20211734 A1 PE20211734 A1 PE 20211734A1 PE 2021001115 A PE2021001115 A PE 2021001115A PE 2021001115 A PE2021001115 A PE 2021001115A PE 20211734 A1 PE20211734 A1 PE 20211734A1
Authority
PE
Peru
Prior art keywords
disease
peptide analogs
conotoxin peptide
pain
alpha
Prior art date
Application number
PE2021001115A
Other languages
English (en)
Inventor
Jose Mercado
Eric J Tarcha
Jeffrey J Posakony
Shawn Iadonato
Original Assignee
Kineta Chronic Pain Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Chronic Pain Llc filed Critical Kineta Chronic Pain Llc
Publication of PE20211734A1 publication Critical patent/PE20211734A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta referido a analogos de peptidos de alfa-conotoxina, los cuales incluyen a los analogos de peptidos de alfa-conotoxina que se unen de una forma covalente al polietilen glicol (PEG), y composiciones farmaceuticas de tales analogos de peptidos de alfa-conotoxina. Estos analogos se emplean para tratar o prevenir una afeccion por medio de la inhibicion de un receptor de acetilcolina nicotinico (nAChR) que contiene alfa9, como en el caso del dolor o la inflamacion, especificamente inflamacion cronica, enfermedad reumatica, sepsis, fibromialgia, enfermedad inflamatoria del intestino, sarcoidosis, endometriosis, fibromas uterinos, una enfermedad inflamatoria de la piel, afeccion inflamatoria de los pulmones, enfermedad asociada con la inflamacion del sistema nervioso, enfermedad periodontal, y enfermedad cardiovascular.
PE2021001115A 2019-01-04 2019-01-04 Analogos de peptidos de conotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias PE20211734A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/012307 WO2020142102A1 (en) 2019-01-04 2019-01-04 Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions

Publications (1)

Publication Number Publication Date
PE20211734A1 true PE20211734A1 (es) 2021-09-06

Family

ID=65244618

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001115A PE20211734A1 (es) 2019-01-04 2019-01-04 Analogos de peptidos de conotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias

Country Status (15)

Country Link
EP (1) EP3906253A1 (es)
JP (1) JP2022522935A (es)
KR (1) KR20210116505A (es)
CN (1) CN113966339A (es)
AU (1) AU2019418319A1 (es)
BR (1) BR112021013302A2 (es)
CA (1) CA3125383A1 (es)
CL (1) CL2021001775A1 (es)
CO (1) CO2021008845A2 (es)
CR (1) CR20210363A (es)
IL (1) IL284574A (es)
MX (1) MX2021008070A (es)
PE (1) PE20211734A1 (es)
SG (1) SG11202106847SA (es)
WO (1) WO2020142102A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230033485A (ko) 2021-09-01 2023-03-08 삼성전자주식회사 저장 장치 및 그의 동작 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717775B2 (en) * 2006-07-18 2017-08-01 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
WO2009126292A2 (en) * 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
EP3215172B1 (en) 2014-11-07 2023-04-26 Kineta Chronic Pain, Llc. Modifications and uses of conotoxin peptides

Also Published As

Publication number Publication date
MX2021008070A (es) 2021-10-13
WO2020142102A9 (en) 2020-11-19
WO2020142102A1 (en) 2020-07-09
CN113966339A (zh) 2022-01-21
CA3125383A1 (en) 2020-07-09
SG11202106847SA (en) 2021-07-29
EP3906253A1 (en) 2021-11-10
CO2021008845A2 (es) 2021-10-29
AU2019418319A1 (en) 2021-07-22
KR20210116505A (ko) 2021-09-27
JP2022522935A (ja) 2022-04-21
CL2021001775A1 (es) 2022-05-27
CR20210363A (es) 2021-12-10
BR112021013302A2 (pt) 2021-09-14
IL284574A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
CY1123211T1 (el) Meθοδoi γia th θepaπeytikh antimetωπισh ή thn προληψη thς hmikpaniaς
CY1121492T1 (el) Φαρμακευτικος συνδυασμος 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης και πρεγκαμπαλινης ή γκαμπαπεντινης
BR112017018656A2 (pt) bactéria modificada para tratar doenças que se beneficiam a partir de inflamação intestinal reduzida e/ou fortalecimento da barreira mucosa intestinal
ECSP20018586A (es) Compuestos que contienen pirazolopirimidinona y sus usos
CL2016000408A1 (es) Composiciones farmaceuticas que contienen diastereomeros macrolidos, metodos para su sintesis y usos terapeuticos.
BR112015021222A2 (pt) inibidores de ras e usos dos mesmos
NI201800008A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
BR112017019779A2 (pt) composto, e, composição farmacêutica
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
GT200600297A (es) Nuevos anticuerpos anti-madcam
PE20180128A1 (es) Compuestos antisenescentes y usos de los mismos
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
CL2017003152A1 (es) Composiciones de hidroxipropil beta-ciclodextrina y métodos
CY1117118T1 (el) Φαρμακευτικος συνδυασμος για την αγωγη του πονου
CY1118081T1 (el) Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
CO2016000671A1 (es) Construcciones de variantes de sirp-alfa y sus usos
MX2018004043A (es) Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
BR112016007462A2 (pt) fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite
CL2022000729A1 (es) Derivado de heteroarilamidopiridinol y composición farmacéutica que comprende el mismo como ingrediente activo para prevención o tratamiento de enfermedad autoinmune
CY1125085T1 (el) Αρωματικα αμιδια καρβοξυλικου οξεος ως ανταγωνιστες υποδοχεα βραδυκινινης β1
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
CU20220016A7 (es) Proteínas de fusión terapéuticas